TMDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TMDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, TransMedics Group's Future 3-5Y EPS without NRI Growth Rate is N/A.
For the Medical Devices subindustry, TransMedics Group's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where TransMedics Group's Future 3-5Y EPS without NRI Growth Rate falls into.
TransMedics Group (NAS:TMDX) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Thank you for viewing the detailed overview of TransMedics Group's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Tamer I Khayal | officer: Chief Commercial Officer | TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
Edward M Basile | director | 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
Waleed H Hassanein | director, officer: President & CEO | TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
Nicholas Corcoran | officer: See Remarks | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
James R Tobin | director | C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Anil P. Ranganath | officer: See Remarks | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Stephen Gordon | officer: Chief Financial Officer | 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
David Weill | director | 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Miriam Provost | officer: VP of US Regulatory & FDA Rel. | 2000 MINUTEMAN ROAD, ANDOVER MA 01810 |
John F Carey | officer: VP of Operations | 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Laura Damme | officer: VP, Clinical Affairs | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Stephanie Lovell | director | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Kania Edwin M Jr | director | |
Rakesh P. Godhani | officer: Chief Digital Officer | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
John F Sullivan | officer: VP of Quality & Engineering | 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
From GuruFocus
By GuruFocus News • 10-04-2024
By GuruFocus News • 12-05-2024
By GuruFocus News • 12-03-2024
By GuruFocus Research • 10-01-2024
By GuruFocus News • 10-29-2024
By GuruFocus News • 11-27-2024
By GuruFocus News • 10-09-2024
By GuruFocus News • 10-21-2024
By GuruFocus News • 11-07-2024
By PRNewswire • 11-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.